Latrepirdine

Summary

Latrepirdine (CHEMBL589390) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including alzheimer disease and huntington disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 25
• Chemistry: 319.4 Da · C21H25N3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL589390
Name	Latrepirdine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	197033
Molecular formula	C21H25N3
Molecular weight	319.4
InChIKey	JNODQFNWMXFMEV-UHFFFAOYSA-N

SMILES: CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C

IUPAC name: 2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole

Also known as: Dimebolin, Dimebon, Latrepirdina, Latrepirdine, Pf-01913539, SID85146210, LATREPIRDINE, SID104223880, latrepirdine; Dimebon dihydrochloride, Dimebon; Dimebolin

Parent form; salt/anhydrous children: CHEMBL1088975, CHEMBL2105703

Patent coverage: 171 distinct patent families (466 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 319 (68%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 26 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Glutamate receptor ionotropic, NMDA 2B, Glutamate NMDA receptor; GRIN1/GRIN2A, Cholinesterase, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1D, D(2) dopamine receptor.

Bioactivity

ChEMBL activities: 40 potent at pChembl ≥ 5 of 45 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR7	8.1	Ki	8	nM	CHEMBL_ACT_24961684
HTR7	8.1	Ki	7.94	nM	CHEMBL_ACT_3089628
HTR7	8.1	Ki	8	nM	CHEMBL_ACT_3264564
HTR7	7.83	Ki	14.67	nM	CHEMBL_ACT_25741246
HTR6	7.58	Ki	26	nM	CHEMBL_ACT_15035160
HTR6	7.58	Ki	26	nM	CHEMBL_ACT_3264602
HTR6	7.47	Ki	34	nM	CHEMBL_ACT_24961700
HTR6	7.47	Ki	33.88	nM	CHEMBL_ACT_3089627
HTR6	7.47	Ki	34	nM	CHEMBL_ACT_3264563
ADRA2B	7.34	Ki	45.77	nM	CHEMBL_ACT_25741235
ADRA1A	7.22	Ki	60.26	nM	CHEMBL_ACT_3089622
HTR2A	7.21	Ki	61.66	nM	CHEMBL_ACT_3089625
HTR2C	7.12	Ki	75.86	nM	CHEMBL_ACT_3089626
HTR2C	7.12	Ki	76	nM	CHEMBL_ACT_3264562
HTR5A	6.97	Ki	107.4	nM	CHEMBL_ACT_25741244
ADRA2A	6.96	Ki	109.7	nM	CHEMBL_ACT_3089623
P31388	6.92	Ki	119	nM	CHEMBL_ACT_3264603
HTR6	6.84	Ki	143.9	nM	CHEMBL_ACT_25741245
HRH1	6.8	IC50	158	nM	CHEMBL_ACT_3089631
HRH1	6.8	IC50	160	nM	CHEMBL_ACT_6224475
HRH2	6.67	Ki	215.2	nM	CHEMBL_ACT_25741239
ADRA1A	6.38	Ki	414.3	nM	CHEMBL_ACT_25741231
HTR1D	6.38	Ki	418.5	nM	CHEMBL_ACT_25741240
DRD3	6.34	Ki	461.4	nM	CHEMBL_ACT_25741238
HTR2B	6.22	Ki	603.2	nM	CHEMBL_ACT_25741243
DRD2	6.2	Ki	631	nM	CHEMBL_ACT_3089624
ADRA2A	6.14	Ki	729	nM	CHEMBL_ACT_25741234
HTR2A	6.14	Ki	725.8	nM	CHEMBL_ACT_25741242
ADRA1D	6.12	Ki	767.2	nM	CHEMBL_ACT_25741233
HTR6	6.05	IC50	890	nM	CHEMBL_ACT_3264550

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	3	MONDO:0004975	MONDO:0004975
Huntington disease	3	MONDO:0007739	MONDO:0007739
liver failure	1	MONDO:0100192	MONDO:0100192

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
PHASE1	12
PHASE3	8
PHASE2	4
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00675623	PHASE3	COMPLETED	A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer’s Disease
NCT00829374	PHASE3	COMPLETED	Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer’s Disease on Donepezil
NCT00838110	PHASE3	COMPLETED	A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer’s Disease
NCT00920946	PHASE3	COMPLETED	A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
NCT00939783	PHASE3	TERMINATED	An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer’s Disease
NCT00954590	PHASE3	TERMINATED	A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer’s Disease
NCT01085266	PHASE3	TERMINATED	An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
NCT01152216	PHASE3	TERMINATED	An Extension of the CONCERT Protocol (DIM18)
NCT00377715	PHASE2	COMPLETED	Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer’s Disease
NCT00387270	PHASE1/PHASE2	COMPLETED	Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington’s Disease
NCT00497159	PHASE2	COMPLETED	A Study of the Novel Drug Dimebon in Patients With Huntington’s Disease
NCT00704782	PHASE2	TERMINATED	Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer’s Disease
NCT01066481	PHASE2	WITHDRAWN	A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer’s Disease
NCT00788047	PHASE1	COMPLETED	A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
NCT00824590	PHASE1	COMPLETED	A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
NCT00825084	PHASE1	COMPLETED	A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects
NCT00827034	PHASE1	COMPLETED	A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
NCT00829816	PHASE1	COMPLETED	Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil
NCT00831506	PHASE1	COMPLETED	Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects
NCT00831532	PHASE1	COMPLETED	Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function
NCT00907322	PHASE1	COMPLETED	A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults
NCT00931073	PHASE1	COMPLETED	A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
NCT00975481	PHASE1	COMPLETED	A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
NCT00988624	PHASE1	COMPLETED	A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)
NCT00990613	PHASE1	COMPLETED	A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).